Hereditary and sporadic laminopathies are caused by mutations in genes encoding lamins, their partners, or the metalloprotease ZMPSTE24/FACE1. Depending on the clinical phenotype, they are classified as tissue-specific or systemic diseases. The latter mostly manifest with several accelerated aging features, as in Hutchinson-Gilford progeria syndrome (HGPS) and other progeroid syndromes. MicroRNAs are small noncoding RNAs described as powerful regulators of gene expression, mainly by degrading target mRNAs or by inhibiting their translation. In recent years, the role of these small RNAs has become an object of study in laminopathies using in vitro or in vivo murine models as well as cells/tissues of patients. To date, few miRNAs have been reported to exert protective effects in laminopathies, including miR-9, which prevents progerin accumulation in HGPS neurons. The recent literature has described the potential implication of several other miRNAs in the pathophysiology of laminopathies, mostly by exerting deleterious effects. This review provides an overview of the current knowledge of the functional relevance and molecular insights of miRNAs in laminopathies. Furthermore, we discuss how these discoveries could help to better understand these diseases at the molecular level and could pave the way toward identifying new potential therapeutic targets and strategies based on miRNA modulation.
| LAMINS AND LAMINOPATHIES
Lamins are type V intermediate filament proteins specifically expressed in the nucleus of eukaryotic cells. They are divided into A-type and B-type families. LMNA encodes A-type lamins produced by alternative splicing of its pre-mRNA. The two major isoforms of this A-type include lamin A and lamin C, but minor isoforms have also been described: lamin AD10, lamin C2 (Furukawa, Inagaki & Hotta, 1994; Lin & Worman, 1993; Machiels et al., 1996) , and more recently LMNAD447 and LMNAD297 (DeBoy et al., 2017) . Lamins A and C are mainly expressed in the nucleus of differentiated somatic cells. Concerning B-type lamins, LMNB1 encodes lamin B1, whereas LMNB2 encodes lamins B2 and B3 by alternative splicing (Elkhatib et al., 2015; Furukawa et al., 1994; Feng Lin & Worman, 1995) .
Lamins B1 and B2 are expressed in nearly all somatic cells, while lamin B3 is a specific spermatid type.
B-type lamins and the lamin A are produced as precursors forms called "prelamins," which undergo several maturation steps before their importation into the nucleus. Firstly, the cysteine of the CAAX box in the C-terminal domain of these prelamins is farnesylated by a farnesyltransferase. This process leads to the prelamin anchoring into the endoplasmic reticulum membrane on its cytosolic leaflet. Secondly, the AAX sequence is cleaved by FACE1/ZMPSTE24 or by FACE2/Rce1. Thirdly, the cysteine residue on which the farnesyl group was previously fixed is carboxymethylated by a isoprenylcysteine carboxyl methyltransferase (Cau et al., 2014) . After this step, B-type lamins are mature and remain farnesylated. As they carry a nuclear localization signal (NLS) in their tail domain, they are imported through the nuclear pore complex (NPC) and remain anchored in the inner nuclear membrane (INM) of the nuclear envelope. For this reason, mature lamins B (B1, B2 and B3) are only present in the nuclear lamina, a protein meshwork at the nuclear periphery, close to the INM. Prelamin A undergoes a fourth and last maturation step, corresponding to the cleavage of the 15 C-terminal amino acids by the metalloproteinase FACE1/ZMPSTE24. Lamin C, a splicing variant of lamin A missing the 98 carboxy terminal amino acids, is directly translated into a mature protein. As mature lamin A and lamin C are not farnesylated, they are not directly anchored in a membrane. They bear an NLS leading to their importation into the nucleoplasm. In the nucleus, lamins A and C are constituents of the nuclear matrix: (i) the lamina where they interact with B-type lamins, with several nuclear envelope transmembrane partner proteins (NETs) of the INM and with the NPC, and (ii) the internal nuclear meshwork forming a component of the nucleoskeleton (Cau et al., 2014; Gruenbaum & Foisner, 2015; Turgay et al., 2017) . This lamin meshwork plays a major role in cell structure by conferring the architecture of the nucleoplasm and maintaining the nuclear shape (Ungricht & Kutay, 2017) . Lamins are essential for chromatin organization via the lamin-associated domains (LAD), which are genomic regions that make contact with the nuclear lamina (van Steensel & Belmont, 2017) . Lamins are also involved in many nuclear functions, such as gene expression, DNA replication, and repair (Gruenbaum & Foisner, 2015; Naetar, Ferraioli & Foisner, 2017) . A-type lamins are involved in mechanosignaling and mechanosensing and contribute to nuclear stiffness, whereas B-type lamins are involved in nucleus elasticity.
The importance of lamins in many physiological mechanisms explains the wild spectrum of diseases linked to these proteins.
Hereditary laminopathies are therefore caused by mutations in genes encoding lamins (primary forms) or proteins implicated in their maturation, such as ZMPSTE24, and in genes encoding their partners (secondary forms; Schreiber & Kennedy, 2013; Worman, 2012; Worman & Bonne, 2007) . Laminopathies can also be acquired. For example, they can have an iatrogenic origin, as in HIV patients treated with protease inhibitors. Most molecules of this class inhibit ZMPSTE24 function, resulting in the blockage of prelamin A maturation and its accumulation in nuclei, leading to clinical manifestations of lipodystrophy syndrome (B er eziat et al., 2011; Caron et al., 2007; Coffinier et al., 2008; Miranda et al., 2007) . The first hereditary laminopathy described was Emery-Dreifuss muscular dystrophy in 1999 (Bonne et al., 1999) . Since then, the number of these diseases has increased. Mutations in LMNA or ZMPSTE24 cause many different phenotypes, which can be classified in multisystem diseases or tissue-specific phenotypes (Worman, 2012; Worman & Bonne, 2007) . Table 1 summarizes this classification: The multisystem diseases correspond mostly to accelerated aging disorders including progeria and other progeroid syndromes, whereas the tissue-specific diseases contain lipodystrophic syndromes, striated muscle diseases, and an axonal peripheral neuropathy. It is of note that overlapping phenotypes exist, such as mandibuloacral dysplasia, which is a combination of progeroid disorder and partial lipodystrophy (Agarwal, Kazachkova, Ten & Garg, 2008) . Mutations in B-type lamins have also been described, enlarging the field of laminopathies. Thus, heterozygous mutations in LMNB2 have been reported to predispose to the development of acquired partial lipodystrophy (APLD), also called "Barraquer-Simons syndrome" (Hegele et al., 2006) , and duplication of LMNB1 leads to adult-onset autosomal-dominant leukodystrophy (ADLD; Padiath et al., 2006) .
| MICR ORNAS
MicroRNAs (miRNAs) are small noncoding RNAs of 18-25 nucleotides (nt) in length. The first described was lin-4 in C. elegans in 1993 (Lee, Feinbaum & Ambros, 1993) . To date, the specific database miRbase lists 2,588 mature miRNAs for Homo sapiens (hsa; Griffiths-Jones, Grocock, van Dongen, Bateman & Enright, 2006) , and 66,160 articles are referenced in PubMed using the keyword "microRNA," with a spectacular increase for 10 years. miRNA genes are present in intergenic regions with an independent promoter (52%), in introns (40%), or less frequently in exons (8%). In these last two cases, the expression of the miRNA is linked to transcription of the host gene (Hsu et al., 2006; Rodriguez, Griffiths-Jones, Ashurst & Bradley, 2004 by RNA polymerase II as a large primary transcript (>1 kb) called "pri-miRNA." The pri-miRNA is recognized by the microprocessor complex, which contains DGCR8 and the RNase III enzyme Drosha (Denli, Tops, Plasterk, Ketting & Hannon, 2004; Han et al., 2004) . In the nucleus, Drosha cleaves the pri-miRNA into a 70 nt stem-loop precursor called "pre-miRNA" (Lee et al., 2003) . The pre-miRNA is then exported to the cytoplasm using exportin 5 and the small Ran GTPase (Bohnsack, Czaplinski & Gorlich, 2004; Yi, Qin, Macara & Cullen, 2003) . In the cytoplasm, the pre-miRNA is therefore cleaved by the endonuclease Dicer into a % 25 nt duplex miRNA (Hutv agner et al., 2001 ). This duplex is bound by the Argonaute protein (AGO) in a complex called "RNA-induced silencing complex" (RISC), which eliminates one strand of the duplex to conserve the guide strand corresponding to the mature %25 nt miRNA (Kobayashi & Tomari, 2016) . This mature miRNA, retained in RISC, recognizes the target transcripts by complementarity to the seed region of the miRNA. to interact with many target mRNAs and to regulate their expression (Gennarino et al., 2012; Helwak et al., 2013; Hendrickson et al., 2009; Tsang, Ebert & van Oudenaarden, 2010) . Currently, 64% of the human miRNAs belong to seed families, which correspond to microRNAs sharing the same or a highly similar seed region (Kozomara & Griffiths-Jones, 2011). As the seed region is essential to recognize mRNA, several microRNAs can target the same mRNA and therefore act together to modulate the expression of this mRNA (Guo, Ingolia, Weissman & Bartel, 2010; Hausser & Zavolan, 2014; Hendrickson et al., 2009 ). Since their discovery, miRNAs have been described in an impressing list of physiological and pathological pathways (Hammond, 2015) . For example, miRNAs are central players during development (e.g., neural or cardiac; Abernathy & Yoo, 2015; Porrello, 2013; Reinhart et al., 2000) or immunity (Zhu, Pan & Qian, 2013) . They play an important role in all cellular processes, such as cell proliferation (Johnson et al., 2007; Navarro & Lieberman, 2010) , differentiation (Navarro & Lieberman, 2010) , and apoptosis (Ghodgaonkar et al., 2009) . They have been largely studied in cancer, in which they are described to function as oncogenes or tumor suppressor genes and are grouped under the term "oncomiRs" (Bracken, Scott & Goodall, 2016; Hayes, Peruzzi & Lawler, 2014) . Several miRNAs are considered organ/tissue-specific; for example, miR-122 is liver-specific (Lagos-Quintana et al., 2002) , and miR-1, miR-206, and miR-133 families are called "myomiRs" (Mok, Lozano-Velasco & M€ unsterberg, 2017; van Rooij, Liu & Olson, 2008) . Moreover, in some cases, miRNAs have been associated with genetic diseases: A mutation of the miR-24 target site in Slitrk1 leads to Tourette syndrome, whereas a mutation in the seed region of miR-96 leads to autosomal-dominant nonsyndromic hearing loss (Bandiera, Hatem, Lyonnet & Henrion-Caude, 2010) . As in all these fields, miRNAs have also been studied in laminopathies. In the next sections, we will present the current knowledge of the different miRNAs linked to laminopathies (Table 2) . knock-in mice (in which a 5 nt mutation was introduced into the predicted miR-9 binding site of prelamin A 3 0 UTR) and Lmna plao-utr mice (in which prelamin A 3 0 UTR was replaced by lamin C 3 0 UTR; Jung et al., 2014) , they demonstrated that miR-9 regulates lamin A or prelamin A expression in the central nervous system by directly targeting their common 3 0 UTR on mRNAs. These results were confirmed by Nissan et al. (2012) using in vitro models of neural precursors and neurons of patients with HGPS. They developed an induced pluripotent stem cell (iPSC) model generated from dermal fibroblasts, which they secondarily derived in neural stem cells, telencephalic neurons, and mesenchymal stem cells (MSC-iPSC) as positive controls. In the wild-type context, lamin A was not expressed in neurons. The transfection of pre-miR-9 in MSC-iPSC generated a 66% decrease in lamin A protein, whereas lamin C increased by 50%. In HGPS MSCiPSC, lamin A and progerin decreased by 35% and 38%, respectively, whereas lamin C increased by 55% after pre-miR-9 transfection.
| MIRNAS IN
Moreover, the abnormal blebs on nuclei decreased by 48% after transfection of pre-miR-9 in HGPS MSC-iPSC, suggesting a protective effect of miR-9 in neurons of patients with HGPS. They also confirmed the direct targeting of miR-9 on lamin A 3 0 UTR using a luciferase reporter assay. Based on this interesting discovery, Fong and colleagues hypothesized that an induced ectopic expression of progerin in neurons would lead to neuropathy in vivo. They generated the Lmna HG-C mouse model, corresponding to the Lmna HG/+ mouse, for which the 3 0 UTR binding site of miR-9 in prelamin A transcript was removed. Interestingly, these mice, which produced progerin in the brain as expected, did not develop pathology in the central nervous system. Surprisingly, they developed achalasia, a gastrointestinal pathology characterized by a dilated esophagus and reduced amounts of muscle within the muscularis externa. The authors suspected that neurons of the central nervous system were less susceptible to the toxicity of progerin than the gastrointestinal tract (Yang et al., 2015) . All these studies demonstrate that miR-9 is a brain-specific miRNA physiologically inhibiting lamin A expression in neurons, which could explain the absence of neuronal disorders in patients with HGPS by preventing progerin accumulation and its associated toxic effects. (Jung et al., , 2014 Mariño et al., 2010; Nissan et al., 2012; Ugalde, Español et al., 2011; Ugalde, Ramsay et al., 2011; Xiong et al., 2015; Yu et al., 2013; Zhang et al., 2017) miR-637, and miR-671-5p. As expected, miR-9 belonged to this list. Second, they listed all the predicted RNAs potentially targeted by these 11 miRNAs. They considered RNAs as ceRNAs if they shared at least three target miRNAs with prelamin A mRNA. Seventeen gene transcripts were considered as potential ceRNAs as they are predicted to be co-regulated with prelamin A mRNA. Surprisingly, four belong to the miRNA processing machinery: DICER1 encoding Dicer, RNEASEN encoding Drosha, and EIF2C1 and EIF2C2 encoding Argonaute proteins. However, the relationship between these proteins and lamin A needs to be clarified. Interestingly, the authors also described a putative co-regulation of mRNAs involved in the cell cycle (TP53, CDKN1A, CDC25A, and CDK6) or inflammation and angiogenesis (NFKB1, IL1B, and VEGFA). Finally, these predictions of ceRNAs must be experimentally confirmed, and their potential roles in HGPS, and more largely in laminopathies, need to be clarified. 
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Conversely, Tang et al. (2016) reported differentially expressed miRNAs in fibroblasts of patients with Werner syndrome compared to controls. Using ingenuity pathway analysis, they identified 18 miRNAs that were linked to 218 target genes that may contribute to Werner syndrome pathophysiology (Tang et al., 2016) . It could be interesting to study the role of the best candidates potentially linked to the aging features and evaluate these miRNAs in the context of atypical Werner syndrome.
Finally, several studies have focused on the role of miRNAs during physiological aging, which enter in the field of "geromiRs" as already discussed above. In this context, miRNAs can regulate prelamin A/lamin A expression to influence physiological aging (Yu et al., 2013 
| miRNAs in lipodystrophic syndromes
Mutations in LMNA also cause adipose tissue pathologies. The autoso- Therefore, this epigenetic modification could at least in part explain the lipodystrophic phenotype in patients.
As Yu et al. (2013) showed that miR-141-3p decreases 
| miRNAs in striated muscle diseases
Several laminopathies affect striated muscles, which include skeletal muscle and/or cardiac muscle. Among them, Emery-Dreifuss muscular dystrophy (EDMD) and limb-girdle muscular dystrophy 1B (LGMD1B) are two dystrophic muscle pathologies presenting with muscle weakness and wasting and clinically differ in the localization of the affected muscles. They are both associated with dilated cardiomyopathy (Bonne et al., 1999; Muchir et al., 2000; Raffaele Di Barletta et al., 2000) . Several types of EDMD laminopathies have LGMD types 2C and 2D, Duchenne muscular dystrophy, and hypertrophic cardiomyopathy. Among them, only EDMD was classified as laminopathy (mutations implicated in LGMD2C and 2D concerned gamma-sarcoglycan gene and alpha-sarcoglycan gene, respectively). The EDMD mouse model was a knock-in carrying the p.H222P LMNA mutation. The authors performed a first miRNome by screening 517 miRNAs and a second by validating 87 of the miRNAs selected in this first miRNome, including miRNAs known to be expressed in normal and pathological muscle. In the EDMD mouse model, two miRNAs, miR-200a and miR-146b, were upregulated, and six were downregulated (miR-1, miR-130a, miR-133a, miR-133b, miR-151-3p, and miR-339-3p). Concerning miR-200a, deregulation of this miRNA was not specific to the EDMD mouse model, as it was also upregulated in the hypertrophic cardiomyopathy model, whereas it was downregulated in the three other models of muscular dystrophy. Among the six downregulated miRNAs in the EDMD mouse model, miR-1, miR-133a, and miR-133b (three muscle-specific miRNAs; Agarwal et al., 2008; van Rooij et al., 2008) were upregulated in the three muscular dystrophy models linked to the dystrophin-associated protein complex and characterized by massive muscle fiber destruction (Duchenne muscular dystrophy, LGMD2C and 2D).
Finally, only miR-130a and miR-339-3p were specifically downregulated in the EDMD mouse model and could therefore be specific biomarkers for this pathology. However, a limitation of this study is that miRNomes were performed using a pool of sera from several mice. Thus, the downregulation of miR-130a and miR-339-3p needs to be confirmed independently in several mice. Moreover, the deregulated miRNAs identified in the sera of EDMD mouse models were different from those identified as deregulated in muscle biopsies from patients with EDMD (Sylvius et al., 2011) and could be linked to other processes not directly related to the muscle pathology.
Koch and Holaska (2012) studied miRNA expression in X-linked Emery-Dreifuss muscular dystrophy, which is caused by mutations in emerin (EMD). They performed miRNA expression profiling on emerinnull mouse myogenic progenitor cells compared to wild-type controls.
Interestingly, they found an upregulation of miR-100, which was already described by Sylvius et al. (2011) , in muscle biopsies of patients suffering from skeletal muscle dystrophy and/or cardiac disorders linked to LMNA mutations. Contrarily, miR-192, which was upregulated in Sylvius et al. (2011) , was found to be downregulated in this study.
Using mRNA profiling, this study on myogenic progenitors derived from emerin-null mice also identified disruptions in the Notch, Wnt, TGF-b, and IGF pathways, but the authors did not link these defects to miRNA deregulation. Thus, it would be interesting to integrate the data (miRNome and transcriptome) in a systems biology approach in the future.
Finally, DICER deletion in the heart leads to dilated cardiomyopathy followed by death in the first days of life (Chen et al., 2008) . These data suggest that miRNAs are fundamental for normal cardiac development. miRNA expression has been studied in several congenital heart diseases (e.g., hypoplastic heart syndrome, tetralogy of Fallot, ventricular septal defects, and Holt-Oram syndrome; Hoelscher et al., 2017) . However, no study has focused on dilated cardiomyopathy type 1A and "Heart-Hand" syndrome linked to lamins.
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| miRNAs in peripheral neuropathy
Charcot-Marie-Tooth (CMT) disease is an inherited neuromuscular disorder presenting clinical and genetic heterogeneity. The disease is characterized by sensory and motor neuropathies (e.g., muscle weakness, foot deformities, and electrophysiological changes). The autosomal-recessive form of axonal CMT linked to LMNA is classified as type 2B1 (OMIM #605588; De Sandre-Giovannoli et al., 2002) . No miRNA profiling has been performed in this subtype, which is classified as laminopathy.
Another form of CMT type 2 (CMT2F, OMIM #606595) is due to mutations in HSPB1, encoding HspB1, also called Hsp27, which is a small heat shock protein (Houlden et al., 2008) . In this form, overexpression of miR-20a and miR-128 has been associated with decreased PDZ-RhoGEF regulating RhoA activity, which could lead to the deregulation of neurite growth (Sun, Zhou, Fink & Mata, 2013) .
| miRNAs in laminopathy affecting LMNB1
Lamins B1 and B2 have been described to play an important role during brain development, especially in neurons (Young, Jung, Coffinier & Fong, 2012) . The autosomal-dominant leukodystrophy (ADLD, OMIM #169500) is the only laminopathy currently linked to the gene LMNB1, mainly caused by its duplication (Padiath et al., 2006) . Clinically, this disease is a progressive degenerative neurological disorder with cerebellar, autonomic, and pyramidal abnormalities. White matter degeneration with severe myelin loss is observed in the brain with the preservation of oligodendroglia. Lamin B1 plays a key role in neuronal migration, as has been shown in different mouse models. It has been evidenced that a lack of lamin B1 expression causes defects in the division of neural progenitor cells, accelerates cell cycle exit, and enhances apoptosis in the cerebral cortex (Lin, Heng, Pt a cek & Fu, 2014) . Conversely, the overexpression of lamin B1 leads to demyelination and perturbation of the inner nuclear membrane proteins, nuclear pore transport, and chromatin organization in neural cell lines. Therefore, the overexpression of lamin B1 in the mouse brain reproduces the symptoms observed in patients with ADLD. Lin et al. (2013) provided new mechanisms of lamin B1 regulation, implicating miR-23a (Lin & Fu, 2009; Lin et al., 2013) . They first demonstrated that lamin B1 expression was developmentally regulated as the protein decreased in the mouse brain from birth to 300 days of age, while miR-23a levels progressively increased in parallel. They demonstrated that miR-23a directly targets the 3 0 UTR of lamin B1 and abrogates the adverse effects of lamin B1 on oligodendrocytes. Using a transgenic mouse model overexpressing murine miR-23a (mmu-miR-23a) specifically in oligodendrocytes, they confirmed that miR-23a enhances myelin synthesis. Furthermore, using an RNA-Seq approach on these mice, they demonstrated that in addition to lamin B1, miR-23a also targets PTEN and a long-noncoding RNA (lncRNA) called "2700046G09Rik." They proposed a model whereby miR-23a is a central player in the regulation of myelination. Lamin B1 overexpression decreased myelin gene transcription, generated a myelin mislocalization and decreased its production. miR-23a increases myelination by repressing lamin B1 expression. Furthermore, miR-23a enhances 2700046G09Rik and represses PTEN in oligodendroglia, leading to AKT activation, which promotes myelination (Lin et al., 2014) . This interesting work conducted by Lin and colleagues raised several issues. As miR-23a seems to play a key role in myelination regulation, it would be interesting to compare the expression of this miRNA in patients with ADLD and healthy subjects. Moreover, this study provides a new potential therapeutic approach for ADLD. Dreesen et al. (2013) confirmed in vitro the role of miR-23a on lamin B1 expression using fibroblasts. They demonstrated that lamin B1 transcripts decreased by %20-fold in senescent fibroblasts compared to proliferating fibroblasts, whereas lamin A/C transcripts remained stable. Concomitantly, they found that miR-23a was increased by %2.5-fold in the same senescent cells. Finally, the overexpression of miR-23a in fibroblasts did not significantly reduce lamin B1 mRNA levels but decreased the protein expression by In HGPS, should we imagine treating patients with miR-9 to repress progerin expression in affected tissues and organs (Harhouri et al., in press)? Several limitations of the use of this potential therapeutic approach shall be taken into consideration. The most important limitation is the low specificity of these small RNA molecules on targets, as one microRNA could inhibit several mRNAs, leading to a high theoretical risk of off-target effects. For example, miR-9 is predicted to target 1377, 545, and 683 mRNAs using TargetScan7.1 (Agarwal, Bell, Nam & Bartel, 2015) , miRDB (Wong & Wang, 2015) and PicTar (Krek et al., 2005) , respectively; to date, up to 360 validated targets are listed in miRTarBase (Chou et al., 2016) . Therefore, it will be imperative to evaluate the off-target effects of this miRNA approach or others, in silico, in vitro in cell models and in vivo in animals before progressing to humans.
| CONCLUSION
MicroRNAs have been shown to play crucial roles in physiology and pathologies related to lamins. This class of small noncoding RNAs influences many pathways dysregulated in laminopathies. To date, few studies have focused on miRNAs in these diseases, although the role of these small molecules could be central to their pathophysiology. Future works on miRNAs in laminopathies could provide new insights into these pathologies and perhaps lead to new therapeutic approaches with the ultimate goal of treating patients. 
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